Nanobiotix S.A. RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3...
The world’s first lung cancer vaccination trials have begun in the United Kingdom. Janusz Racz, a 67-year-old lung cancer patient, is the first to receive this...